Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219173 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
A Phase 2 study of Asthma, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 531
- Enrollment target
- 20
- Study locations
NCT07219173 is a Phase 2 study of Asthma that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 531 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT07219173, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 531 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brenipatide
Study Locations (20)
Florida
- AMR Clinical - Doral
- Renstar Medical Research - Ocala
- Avanza Medical Research Center - Pensacola
- USF Health - Tampa
California
- NewportNativeMD, Inc. - Newport Beach
- California Medical Research Associates - Northridge
- Peninsula Research Associates - Rolling Hills Estates
Other
- Consultorios Médicos, Organización del Buen Ayre S.R.L. - Buenos Aires
- Centro de Investigaciones Metabólicas (CINME) - Buenos Aires
- Fundación Respirar - Buenos Aires
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
- Allergy and Clinical Immunology Associates - Pittsburgh
Arizona
- AMR Clinical - Tempe
Colorado
- Asthma & Allergy Associates - Colorado Springs - Colorado Springs
Illinois
- Axis Clinical Trials - Westchester - Westchester
Kentucky
- Allergy & Asthma Specialists, P.S.C. - Owensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 531 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219173
The ClinicalTrials.gov registry entry for NCT07219173 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 531 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (66% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07219173 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Other.
Frequently Asked Questions
What is clinical trial NCT07219173 about?
NCT07219173 is a clinical study titled "A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma". The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
What is the current status of trial NCT07219173?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 531 participants. The study started on 2025-10-22. Estimated completion is 2028-06.
What conditions does trial NCT07219173 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT07219173?
The interventions under investigation include: Placebo (DRUG), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07219173?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219173 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
-
Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.